A Toronto-based research team has identified a new neuroprotective factor that has the potential to help people suffering from the common blinding disease glaucoma.
New frontiers are opening for farmers beyond food and feed to a vast array of industrial and consumer applications.
Orfadin, an oral suspension which is meant to treat hereditary tyrosinemia type 1 (HT-1), has been approved by Health Canada.
A recent forecast expects the global insomnia therapeutics market to reach US$3.45 billion by 2025.
The International pharmaceutical company, Servier Canada is working with the Quebec-based industrial cluster CQDM to fund a research project aimed at preventing diabetes-related kidney diseases.